February 8, 2019 10:32 AM EST
Peer Review

Mor­phoSys taps Baven­cio lead for US op­er­a­tions; Two top FDA of­fi­cials move to in­dus­try

Amber Tong

→ Hav­ing built out a com­mer­cial foot­print in the US and led the launch of Baven­cio for Mer­ck KGaA, David Trexler …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Pfiz­er, GSK add risk of Guil­lain-Bar­ré to RSV vac­cine la­bels at FDA's re­quest

A service from the Financial Times